Premium
LENALIDOMIDE AND RITUXIMAB (ReRi) AS FRONT LINE THERAPY OF ELDERLY FRAIL PATIENTS WITH DIFFUSE LARGE B‐CELLS LYMPHOMA. FIRST PLANNED INTERIM ANALYSIS OF A PHASE II STUDY OF THE FONDAZIONE ITALIANA LINFOMI (FIL)
Author(s) -
Gini G.,
Tani M.,
Bassan R.,
Tucci A.,
Ballerini F.,
Sampaolo M.,
Merli F.,
Re F.,
Annibali O.,
Liberati A.,
Visco C.,
Arcari A.,
Storti S.,
Fabbri A.,
Musuraca G.,
Zilioli V.,
Cox M.,
Luminari S.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.99_2631
Subject(s) - lenalidomide , medicine , rituximab , diffuse large b cell lymphoma , interim analysis , clinical endpoint , population , phases of clinical research , neutropenia , regimen , oncology , surgery , clinical trial , lymphoma , multiple myeloma , toxicity , environmental health